Testosterone Replacement Therapy and Musculoskeletal Health: What Clinicians Should Know

A 58-year-old man presents after a low-trauma fracture. His bone density is lower than expected from his medical history. Another patient, aged 45, reports a gradual loss of muscle strength that has not improved with training.

Neither case confirms hypogonadism. However, both provide a reasonable reason to consider testosterone deficiency as part of the differential diagnosis.

For patients who need a plain-language overview of local assessment and treatment, this guide to testosterone therapy Vancouver explains the process. In clinical practice, the more important question is when testosterone testing is appropriate.

Guidelines do not support routine screening of asymptomatic men. Testing should be prompted by compatible symptoms, physical findings, or associated medical conditions. Joint pain or slower workout recovery alone are not enough.

When testosterone testing makes sense

Low-trauma fractures, reduced bone density, unexplained height loss, and loss of muscle mass or strength may justify considering testosterone deficiency. Sexual symptoms, such as reduced libido or fewer spontaneous erections, make the diagnosis more likely, but no single symptom is specific.

Other possible causes should be assessed at the same time. These may include osteoporosis unrelated to testosterone, medication effects, obesity, sleep apnea, thyroid disease, chronic illness, poor nutrition, and reduced physical activity.

A diagnosis of hypogonadism requires both:

Compatible symptoms or signs
Consistently low testosterone levels

An initially low total testosterone result should normally be confirmed with a second fasting morning measurement. Free testosterone is most useful when total testosterone is close to the lower limit of normal or when a condition affecting sex hormone-binding globulin, or SHBG, may make total testosterone difficult to interpret. It does not need to be included automatically in every initial panel.

For men with confirmed, symptomatic hypogonadism, testosterone therapy may improve bone density and lean body mass. Improvements in muscle strength and physical function are less consistent, and TRT should not be prescribed solely to treat osteoporosis, prevent fractures, or improve exercise recovery.

How testosterone affects bone and muscle

Testosterone influences bone through more than one pathway. It acts through androgen receptors in bone cells and is also converted into estradiol.

Estradiol plays a particularly important role in limiting bone resorption and maintaining bone density in men. In severe hypogonadism, low testosterone and low estradiol can contribute to deterioration of both trabecular and cortical bone, reduced bone mineral density, and increased fracture risk.

A DXA T-score does not capture every part of that risk. Age, previous fractures, glucocorticoid exposure, falls, medical conditions, and other clinical factors also matter.

FRAX can estimate a patient’s 10-year probability of hip and major osteoporotic fracture using several clinical risk factors, with or without femoral-neck bone density. However, standard FRAX does not directly include fall history, so falls must be assessed separately.

Testosterone also promotes muscle protein accretion and can increase muscle-fibre size and lean body mass. However, gaining lean mass does not always translate into a comparable improvement in strength, mobility, or physical performance.

Reduced grip strength, slower recovery, and declining exercise performance may be worth discussing, but they are nonspecific. Evidence that TRT improves tendon or ligament healing remains limited.

What clinical trials show

The Bone Trial was part of the coordinated Testosterone Trials and included men aged 65 or older with repeatedly low testosterone and evidence of impaired sexual or physical function or reduced vitality.

After one year, testosterone treatment significantly increased volumetric bone mineral density and estimated bone strength at both the spine and hip. The effects were larger in the spine than in the hip and larger in trabecular bone than in cortical-rich peripheral bone.

The study used quantitative CT for its primary bone outcomes. On conventional DXA, the increase was clearest at the spine, while the between-group differences at the total hip and femoral neck were not statistically significant. Lean-body-mass findings came from other parts of the Testosterone Trials rather than from the Bone Trial itself.

The later TRAVERSE fracture study showed why improvements in bone density should not automatically be treated as proof of fracture prevention.

Over a median follow-up of 3.19 years, clinical fractures occurred in 3.50% of testosterone-treated participants and 2.46% of those receiving placebo. The hazard ratio was 1.43, with a 95% confidence interval of 1.04 to 1.97.

The reason for this unexpected difference remains uncertain. The results do not negate the measured improvements in bone density, but they show that TRT has not been proven to reduce fractures. It should not replace approved osteoporosis treatment in men who meet criteria for it.

How guidelines position TRT

The Endocrine Society recommends testosterone therapy for appropriately diagnosed men with symptomatic testosterone deficiency after the expected benefits, limitations, risks, and monitoring requirements have been discussed.

That recommendation does not make TRT a general treatment for age-related muscle loss or osteoporosis. It is not recommended as first-line osteoporosis treatment in men with normal testosterone, and it is not a standalone fracture-prevention strategy.

A hypogonadal man with osteoporosis or high fracture risk may need both appropriately monitored testosterone therapy and a standard osteoporosis treatment. Canadian clinicians should also consider Canadian Urological Association guidance and applicable provincial protocols.

Monitoring during treatment

Monitoring should assess whether treatment is producing meaningful clinical benefits while identifying adverse effects early.

Serum testosterone should be measured after treatment begins, usually at three to six months, with the timing adjusted to the formulation being used. Symptoms and adverse effects should also be reviewed during early follow-up and at least annually once treatment is stable.

Hematocrit should be checked:

Before treatment
Three to six months after initiation
Annually thereafter

Under Endocrine Society guidance, a hematocrit above 54% warrants pausing therapy until it falls to a safer level, assessing contributing factors such as hypoxia or sleep apnea, and restarting at an adjusted dose when appropriate. Canadian recommendations use similar monitoring principles, although exact action thresholds can vary slightly.

Prostate monitoring should reflect the patient’s age, baseline risk, preferences, and applicable screening guidance. The British Columbia protocol recommends baseline PSA testing and digital rectal examination, followed by repeat assessment at three and six months and annually if stable. Other guidelines use a more individualized, shared-decision approach.

Blood pressure should also be followed because testosterone products can increase it. Lipid and glucose testing may be appropriate as part of general cardiovascular and metabolic care, but neither is a universal TRT-specific monitoring requirement for every patient.

Repeat DXA is mainly relevant to men who had osteoporosis or abnormal bone density before treatment. It is generally considered after one to two years, rather than being ordered routinely for every patient receiving TRT. DXA evaluates bone-density response and fracture risk. It does not establish the overall safety of testosterone treatment.

Risks that require careful monitoring

An increase in hematocrit is one of the most common clinically important laboratory effects of TRT. Management may involve reducing the dose, changing the formulation, temporarily stopping treatment, or investigating contributing conditions.

In the TRAVERSE cardiovascular trial, transdermal testosterone was noninferior to placebo for major adverse cardiovascular events among middle-aged and older men with confirmed hypogonadism and existing cardiovascular disease or elevated cardiovascular risk.

However, atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often in the testosterone group. These results are reassuring about major cardiovascular events in the population studied, but they should not be generalized to every patient, treatment formulation, or duration of use. Long-term safety remains incompletely established.

Endocrine Society guidance advises against starting TRT in men with uncontrolled heart failure, myocardial infarction or stroke within the previous six months, thrombophilia, or untreated severe obstructive sleep apnea.

Fertility must also be discussed before treatment. Exogenous testosterone suppresses LH and FSH, reduces sperm production, and can cause infertility. It should not be started in men who are actively trying to conceive or planning fertility in the near future without appropriate specialist guidance.

Where TRT fits into musculoskeletal care

For a man with confirmed hypogonadism, TRT can be one part of a broader treatment plan. It does not replace resistance exercise, adequate protein and energy intake, fall prevention, rehabilitation, or standard osteoporosis care.

Evidence that TRT provides an additional functional benefit when added to structured rehabilitation is inconsistent. It should therefore be viewed as treatment for confirmed testosterone deficiency, not as a general recovery or performance aid.

The practical message is straightforward: test selectively, confirm the diagnosis, identify other causes, and monitor treatment on a defined schedule.

TRT can produce measurable improvements in bone density and lean body mass in appropriately selected men. Those benefits should not be confused with proven improvements in physical performance or fracture prevention. Bone health and fracture risk still require their own assessment and treatment plan.

This article is intended for clinical education and general information. It does not replace an individualized diagnostic evaluation or treatment plan.